Researchers found two genetic variants on the interleukin-1 beta (IL-1β) gene that predispose patients from India with systemic lupus erythematosus (SLE) to develop kidney and hematological disease symptoms. The population-based study, “Predisposition of IL-1β (-511 C/T) polymorphism to renal and hematologic disorders in Indian SLE patients,” was…
A Phase 2 study assessing Gazyva (obinutuzumab) plus mycophenolate mofetil (MMF) or mycophenolic acid (MPA) as a treatment for lupus nephritis patients is currently enrolling participants. The Phase 2 NOBILITY trial (NCT02550652) will be conducted by Roche and Genentech to determine if the combination is better at treating kidney…
Inhibition of a natural enzyme that works as a sensor for virus and bacteria invasions may reduce inflammation associated with autoimmune diseases, including systemic lupus erythematosus, according to a recent study. The findings, reported in the study “Small molecule inhibition of cGAS reduces interferon expression in primary macrophages…
Two specific variations in the genetic sequence of the glucocorticoid receptor — which determines how well glucocorticoid regulates metabolism and other key processes — were seen to markedly increase a person’s risk of systemic lupus erythematosus (SLE), a study conducted in China reports. Published in the International Journal of…
New data from an ongoing Phase 3 clinical trial continues to demonstrate that ImmuPharma‘s Lupuzor is safe for the treatment of systemic lupus erythematosus (SLE) patients. To date, all trial participants have reached the six-month stage, and one out of four have completed…
Japan’s Ministry of Health, Labor and Welfare has approved Benlysta (belimumab) as an add-on therapy to treat adult patients with systemic lupus erythematosus (SLE) who cannot receive or don’t respond to existing therapies. The drug, developed by GlaxoSmithKline (GSK), will be available in two formulations, given via intravenous (IV) or subcutaneous (SC)…
The protein OX40L, produced by immune B-cells, plays a key role in the development of systemic lupus erythematosus (SLE) by activating a T-cell subset involved in autoimmunity, new research has found. Inhibition of OX40L B-cells improved lupus symptoms in mice, suggesting that OX40L is a promising new target for lupus treatment. The…
A Brazilian study makes a connection between income, lupus progression and lupus outcomes. The less income a person has, the more likely that their disease will progress faster and that they will have a poor outcome, according to the research, which confirmed a California study’s results. Other factors that the…
ImmunArray and Kindstar Global, two companies focused on the development and marketing of diagnostic tools for acute and chronic immune and neurodegenerative diseases, have joined forces to launch the cost-effective SLE-Key Rule-Out Test for lupus in China. The blood test, which helps clinicians accurately rule out lupus during diagnosis, is expected to enter…
The German Research Foundation has awarded a 13-million-euro grant to a consortium that is trying to develop treatments for autoimmune diseases, such as systemic lupus erythematosus. The four-year grant, equivalent to $14.7 million, was to the TRR130 Transregional Collaborative Research Center, which is working on B-cells: Immunity and Autoimmunity. The…